Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -6.11
- Piotroski Score 4.00
- Grade Buy
- Symbol (THTX)
- Company Theratechnologies Inc.
- Price $1.20
- Changes Percentage (-0.82%)
- Change -$0.01
- Day Low $1.20
- Day High $1.21
- Year High $2.58
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/19/2025
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.58
- Trailing P/E Ratio -2.1
- Forward P/E Ratio -2.1
- P/E Growth -2.1
- Net Income $-23,957,000
Income Statement
Quarterly
Annual
Latest News of THTX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Theratechnologies Inc (THTX) Q3 2024 Earnings Call Highlights: Strong Profitability Amid ...
Adjusted EBITDA guidance for fiscal 2024 has been raised to $17-19 million. The company is confident in FDA approval for EGRIFTA SV batch release in late October and managing inventory closely....
By Yahoo! Finance | 1 month ago -
Theratechnologies Inc. (TSE:TH) Has Found A Path To Profitability
Theratechnologies Inc., a biopharmaceutical company, is nearing breakeven with analysts predicting profitability by 2024. The company is expected to grow 65% year-on-year. Despite negative equity, it ...
By Yahoo! Finance | 5 months ago
